Binkley et al. analyzed mutations in 232 genetically-profiled NSCLC patients and found that about half of the local recurrences, post-radiotherapy occurred in tumors with KEAP1/NFE2L2 mutations, indicating these mutations are major drivers of clinical radioresistance [25]. Here, NFE2L2 is linked to non-small cell lung carcinoma.